J
Jürgen Krauter
Researcher at Hannover Medical School
Publications - 232
Citations - 15649
Jürgen Krauter is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Myeloid leukemia & Transplantation. The author has an hindex of 57, co-authored 217 publications receiving 13470 citations. Previous affiliations of Jürgen Krauter include Hochschule Hannover.
Papers
More filters
Journal ArticleDOI
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Richard F. Schlenk,Konstanze Döhner,Jürgen Krauter,Stefan Fröhling,Andrea Corbacioglu,Lars Bullinger,Marianne Habdank,Daniela Späth,Michael Morgan,Axel Benner,Brigitte Schlegelberger,Gerhard Heil,Arnold Ganser,Hartmut Döhner +13 more
TL;DR: Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, MLL, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.
Journal ArticleDOI
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Stone,Sumithra J. Mandrekar,Ben L. Sanford,Kristina Laumann,Susan Geyer,Clara D. Bloomfield,Christian Thiede,Thomas W. Prior,Konstanze Döhner,Guido Marcucci,Francesco Lo-Coco,Rebecca B. Klisovic,Andrew H. Wei,Jorge Sierra,Miguel A. Sanz,Joseph Brandwein,Theo de Witte,Dietger Niederwieser,Frederick R. Appelbaum,Bruno C. Medeiros,Martin S. Tallman,Jürgen Krauter,Richard F. Schlenk,Arnold Ganser,Hubert Serve,Gerhard Ehninger,Sergio Amadori,Richard A. Larson,Hartmut Döhner +28 more
TL;DR: The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.
Journal ArticleDOI
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Frank G. Rücker,Richard F. Schlenk,Lars Bullinger,Sabine Kayser,Veronica Teleanu,Helena Kett,Marianne Habdank,Carla Maria Kugler,Karlheinz Holzmann,Verena I. Gaidzik,Peter Paschka,Gerhard Held,Marie von Lilienfeld-Toal,Michael Lübbert,Stefan Fröhling,Thorsten Zenz,Thorsten Zenz,Jürgen Krauter,Brigitte Schlegelberger,Arnold Ganser,Peter Lichter,Konstanze Döhner,Hartmut Döhner +22 more
TL;DR: TP53 alteration is the most important prognostic factor in CK-AML, outweighing all other variables, including the MK category, and in multivariable analysis for overall survival, TP53 alterations, white blood cell counts, and age were the only significant factors.
Journal ArticleDOI
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Verena I. Gaidzik,Lars Bullinger,Richard F. Schlenk,Andreas Zimmermann,Jürgen Röck,Peter Paschka,Andrea Corbacioglu,Jürgen Krauter,Brigitte Schlegelberger,Arnold Ganser,Daniela Späth,Andrea Kündgen,Ingo G.H. Schmidt-Wolf,Katharina Götze,David Nachbaur,Michael Pfreundschuh,Heinz A. Horst,Hartmut Döhner,Konstanze Döhner +18 more
TL;DR: AML with RUNX1 mutations are characterized by distinct genetic properties and are associated with resistance to therapy and inferior outcome, and Explorative subgroup analysis revealed that allogeneic hematopoietic stem-cell transplantation had a favorable impact on RFS in RunX1-mutated patients.
Journal ArticleDOI
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.
Sabine Kayser,Konstanze Döhner,Jürgen Krauter,Claus Henning Köhne,Heinz A. Horst,Gerhard Held,Marie von Lilienfeld-Toal,Sibylla Wilhelm,Andrea Kündgen,Katharina Götze,Mathias J. Rummel,David Nachbaur,Brigitte Schlegelberger,Gudrun Göhring,Daniela Späth,Carina Morlok,Manuela Zucknick,Arnold Ganser,Hartmut Döhner,Richard F. Schlenk +19 more
TL;DR: In more intensively treated younger adults, treatment-related toxicity had a major negative impact on outcome, possibly reflecting cumulative toxicity of cancer treatment.